Travere Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Travere Therapeutics' 2025 annual report highlights significant revenue growth from FILSPARI, progress in its FSGS and HCU programs, and strategic partnerships, despite ongoing clinical and market challenges.
NASDAQ
Travere Therapeutics achieved full FDA approval for FILSPARI in IgAN and advanced its pipeline, while managing financial performance amidst restructuring and strategic shifts.
NASDAQ
Travere Therapeutics' 2023 annual report highlights the commercial launch of FILSPARI, progress in clinical trials, and a strategic reorganization.